Clinical Trial IDNCT04120883
Lead SponsorUniversity of Michigan
Principal Investigator
Start Date2020-02-01
Completion Date2022-10-01
Study TypeInterventional
PhasePhase 1/Phase 2
StatusNot yet recruiting


This research study is being done to learn what effect 12 months of treatment with oral hydroxychloroquine (HCQ) will have on the retina in people with retinitis pigmentosa (RP). The hypothesis is that treatment with HCQ is safe and tolerable in patients with autosomal dominant retinitis pigmentosa (adRP) caused by P23H-RHO, and may arrest progression of retinal degeneration by altering the autophagy pathway in photoreceptors. Participants that meet eligibility and agree to the study will be asked to take the study medication (HCQ) for 12 months and have evaluations for up to approximately 18 months from the baseline visit. There will be a total of 6 visits (1 is a phone visit) and will include general examinations, blood work, electrocardiograms, along with special testing of the retina.


Retinitis PigmentosaDrug: Hydroxychloroquine lower dose, Drug: Hydroxychloroquine higher dosePhase 1/Phase 2


AgeGenderAccepts Healthy Volunteers
18 Years and older.AllNo